Mark J. Burk

Mark J. Burk

Auto-generated profile, based on publicly available information

Mark J. Burk

Lassogen, Inc., 3830 Valley Centre Drive, Suite 705-562, San Diego, California 92130, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2021 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
YSYuanyuan Si
Yuanyuan Si
AKAshley M. Kretsch
Ashley M. Kretsch
LDLaura M. Daigh
Laura M. Daigh
MBMark J. Burk
Mark J. Burk
DMDouglas A. Mitchell
Douglas A. Mitchell

11 September 2024 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
SBSusanna E. Barrett
Susanna E. Barrett
SYSong Yin
Song Yin
PJPeter Jordan
Peter Jordan
JBJohn K. Brunson
John K. Brunson
JGJessica Gordon-Nunez
Jessica Gordon-Nunez
DMDouglas A. Mitchell
Douglas A. Mitchell

2 September 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ALAnna Lechner
Anna Lechner
PJPeter A. Jordan
Peter A. Jordan
GCGabriella Costa Machado da Cruz
Gabriella Costa Machado da Cruz
JLJacob Lamson
Jacob Lamson
JGJessica Gordon
Jessica Gordon
MBMark J. Burk
Mark J. Burk

22 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
WSWataru Shihoya
Wataru Shihoya
HAHiroaki Akasaka
Hiroaki Akasaka
PJPeter A. Jordan
Peter A. Jordan
ALAnna Lechner
Anna Lechner
BOBethany K. Okada
Bethany K. Okada
ONOsamu Nureki
Osamu Nureki
Lasso peptides exhibit a unique lariat-like knotted structure imparting exceptional stability and thus show promise as therapeutic agents that target cell-surface receptors. One such receptor is the human endothelin type B receptor (ETB), which is implicated in challenging cancers with poor immunotherapy responsiveness. The Streptomyces-derived lasso peptide, RES-701-3, is a selective inhibitor for ETB and a compelling candidate for therapeutic development. However, meager production from a genetically recalcitrant host has limited further structure-activity relationship studies of this potent inhibitor. Here, we report cryo-electron microscopy structures of ETB receptor in both its apo form and complex with RES-701-3, facilitated by a calcineurin-fusion strategy. Hydrophobic interactions between RES-701-3 and the transmembrane region of the receptor, especially involving two tryptophan residues, play a crucial role in RES-701-3 binding. Furthermore, RES-701-3 prevents conformational changes associated with G-protein coupling, explaining its inverse agonist activity. A comparative analysis with other lasso peptides and their target proteins highlights the potential of lasso peptides as precise drug candidates for G-protein-coupled receptors. This structural insight into RES-701-3 binding to ETB receptor offers valuable information for the development of novel therapeutics targeting this receptor and provides a broader understanding of lasso peptide interactions with human cell-surface receptors.

1 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
WSWataru Shihoya
Wataru Shihoya
HAHiroaki Akasaka
Hiroaki Akasaka
PJPeter A Jordan
Peter A Jordan
ALAnna Lechner
Anna Lechner
BOBethany K. Okada
Bethany K. Okada
ONOsamu Nureki
Osamu Nureki
Lasso peptides exhibit a unique lariat-like knotted structure imparting exceptional stability and thus show promise as therapeutic agents that target cell-surface receptors. One such receptor is the human endothelin ET B receptor, which is implicated in challenging cancers with poor immunotherapy responsiveness. The Streptomyces -derived lasso peptide, RES-701-3, is a selective inhibitor for ET B and a compelling candidate for therapeutic development. However, meager production from a genetically recalcitrant host has limited further structure-activity relationship studies of this potent inhibitor. Here, we report cryo-electron microscopy structures of ET B receptor in both its apo form and complex with RES-701-3, facilitated by a calcineurin-fusion strategy. Hydrophobic interactions between RES-701-3 and the transmembrane region of the receptor, especially involving two tryptophan residues, play a crucial role in RES-701-3 binding. Furthermore, RES-701-3 prevents conformational changes associated with G-protein coupling, explaining its inverse agonist activity. A comparative analysis with other lasso peptides and their target proteins highlights the potential of lasso peptides as precise drug candidates for G-protein-coupled receptors. This structural insight into RES-701-3 binding to ET B receptor offers valuable information for the development of novel therapeutics targeting this receptor and provides a broader understanding of lasso peptide interactions with human cell-surface receptors.

27 November 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
YSYuanyuan Si
Yuanyuan Si
AKAshley M. Kretsch
Ashley M. Kretsch
LDLaura M. Daigh
Laura M. Daigh
MBMark J. Burk
Mark J. Burk
DMDouglas A. Mitchell
Douglas A. Mitchell
Lasso peptides are ribosomally synthesized and post-translationally modified peptide (RiPP) natural products that display a unique lariat-like structure. Owing to a rigid topology, lasso peptides are unusually stable towards heat and proteolytic degradation. Some lasso peptides have been shown to bind human cell-surface receptors and exhibit anticancer properties, while others display antibacterial or antiviral activities. Known lasso peptides are produced by bacteria and genome-mining studies indicate that lasso peptides are a relatively prevalent RiPP class; however, the discovery, isolation, and characterization of lasso peptides are constrained by the lack of an efficient production system. In this study, we employ a cell-free biosynthesis (CFB) strategy to address the longstanding challenges associated with lasso peptide production. We report the successful formation of a diverse array of lasso peptides that include known examples as well as a new predicted lasso peptide from Thermobifida halotolerans . We further demonstrate the utility of CFB to rapidly generate and characterize multisite precursor peptide variants in order to evaluate the substrate tolerance of the biosynthetic pathway. We show that the lasso-forming cyclase from the fusilassin pathway can produce millions of sequence-diverse lasso peptides via CFB with an extraordinary level of sequence permissiveness within the ring region of the lasso peptide. These data lay a firm foundation for the creation of large lasso peptide libraries using CFB to identify new variants with unique properties.